Predictors of symptom resolution in patients with community-acquired pneumonia
- PMID: 11096003
- DOI: 10.1086/317495
Predictors of symptom resolution in patients with community-acquired pneumonia
Abstract
Previous studies have demonstrated that a substantial number of patients with community-acquired pneumonia (CAP) experienced CAP-related symptoms up to 3 months after the completion of antibiotic treatment. We evaluated the frequency of symptoms in a cohort of 535 patients with CAP who presented to a hospital emergency department and completed symptom questionnaires 2 and 6 weeks after the completion of a course of antibiotic therapy. Six weeks after cessation of antibiotic therapy, 64% of patients still reported > or = 1 CAP-related symptoms. Exploratory analyses were performed to identify potential predictors of complete symptom resolution. Logistic regression analysis identified younger age, absence of asthma or chronic obstructive pulmonary disease, and levofloxacin treatment as predictors of complete symptom resolution (all P < .05). Randomized controlled trials should be performed to evaluate the relative efficacy of different antibiotic therapies on the rate of resolution of symptoms.
Similar articles
-
Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting.Arch Intern Med. 2003 Apr 14;163(7):797-802. doi: 10.1001/archinte.163.7.797. Arch Intern Med. 2003. PMID: 12695270
-
Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.Clin Ther. 2008 Feb;30(2):358-71. doi: 10.1016/j.clinthera.2008.01.023. Clin Ther. 2008. PMID: 18343274
-
Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.Diagn Microbiol Infect Dis. 2009 Jan;63(1):52-61. doi: 10.1016/j.diagmicrobio.2008.09.001. Epub 2008 Nov 5. Diagn Microbiol Infect Dis. 2009. PMID: 18990531 Clinical Trial.
-
Levofloxacin in the treatment of community-acquired pneumonia.Expert Rev Anti Infect Ther. 2010 May;8(5):505-14. doi: 10.1586/eri.10.35. Expert Rev Anti Infect Ther. 2010. PMID: 20455679 Review.
-
Placebo-controlled trials of treatments for community-acquired pneumonia: review of the literature and discussion of feasibility and potential value.Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S145-9. doi: 10.1086/591396. Clin Infect Dis. 2008. PMID: 18986281 Review.
Cited by
-
Sex differences in the impact of lower respiratory tract infections on older adults' health trajectories: a population-based cohort study.BMC Infect Dis. 2024 Nov 1;24(1):1227. doi: 10.1186/s12879-024-10131-7. BMC Infect Dis. 2024. PMID: 39482598 Free PMC article.
-
Impact of lower-respiratory tract infections on healthcare utilization and mortality in older adults: a Swedish population-based cohort study.Aging Clin Exp Res. 2024 Jul 17;36(1):146. doi: 10.1007/s40520-024-02808-5. Aging Clin Exp Res. 2024. PMID: 39017735 Free PMC article.
-
Fixed versus individualized treatment for five common bacterial infectious syndromes: a survey of the perspectives and practices of clinicians.JAC Antimicrob Resist. 2023 Aug 1;5(4):dlad087. doi: 10.1093/jacamr/dlad087. eCollection 2023 Aug. JAC Antimicrob Resist. 2023. PMID: 37533760 Free PMC article.
-
Acute organ injury and long-term sequelae of severe pneumococcal infections.Pneumonia (Nathan). 2023 Mar 5;15(1):5. doi: 10.1186/s41479-023-00110-y. Pneumonia (Nathan). 2023. PMID: 36870980 Free PMC article. Review.
-
Silent Hypoxia in COVID-19: A Case Series.Respiration. 2022;101(4):376-380. doi: 10.1159/000520083. Epub 2021 Nov 26. Respiration. 2022. PMID: 34839295 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
